A Study of SRSD216 in Patients With Elevated Lipoprotein (a)

Inclusion Criteria: * Able to comprehend and willing to sign an informed consent form (ICF) and to abide by the study restrictions; * Males or females, of any race; * Body mass index (BMI) between 18.0 and 40.0 kg/m2, inclusive; * Male subjects are not allowed to donate sperm, and female subjects are not allowed to donate eggs from the time the ICF is signed until at least 3 months after the last follow-up. Exclusion Criteria: * Any history or evidence of abnormal bleeding or coagulopathy; or evidence of prolonged or unexplained, clinically significant bleeding, or frequent unexplained bruising or thrombosis; or history of spontaneous bleeding; * Evidence of active or suspected cancer within 3 years prior to screening (non-melanoma skin cancer, localized prostate cancer treated with curative intent, or other in situ carcinoma that does not require systemic therapy and is considered cured for at least 1 years is allowed); * Acute febrile illness within 7 days prior to dose administration or evidence of active infection; * Any major surgery within 3 months prior to screening or plan to have any major surgery during the study; * History of clinically significant hypersensitivity, intolerance, or allergy to any oligonucleotide or GalNAc as determined by the investigator; * Fasting TG≥ 500 mg/dL (5.6 mmol/L) during screening; * Receipt of an investigational drug within 30 days or 5 half-lives of that drug, whichever is longer, prior to dose administration in this study; * Have previously completed or withdrawn from this study or any other study investigating SRSD216 and have previously received SRSD216.